DUBLIN--(BUSINESS WIRE)--The "Organophosphate and Carbamate Poisoning - Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
Organophosphate and Carbamate Poisoning - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Organophosphate and Carbamate Poisoning (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Organophosphate and Carbamate Poisoning (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Organophosphate and Carbamate Poisoning and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical stages are 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.
Organophosphate and Carbamate Poisoning (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Organophosphate and Carbamate Poisoning (Toxicology).
- The pipeline guide reviews pipeline therapeutics for Organophosphate and Carbamate Poisoning (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Organophosphate and Carbamate Poisoning (Toxicology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Organophosphate and Carbamate Poisoning (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Organophosphate and Carbamate Poisoning (Toxicology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Organophosphate and Carbamate Poisoning (Toxicology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Organophosphate and Carbamate Poisoning (Toxicology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Topics Covered:
Introduction
- Report Coverage
Organophosphate and Carbamate Poisoning - Overview
Organophosphate and Carbamate Poisoning - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
Organophosphate and Carbamate Poisoning - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
Organophosphate and Carbamate Poisoning - Companies Involved in Therapeutics Development
- AntoXa Corp
- Countervail Corp
- PlantVax Inc
Organophosphate and Carbamate Poisoning - Drug Profiles
AM-132 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
galantamine hydrobromide - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
PlantVax-1502-HN - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
Recombinant Butyrylcholinesterase for Carbamate and Organophosphate Poisoning - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
RS-194B - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
Small Molecule for Organophosphate Poisoning - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
Small Molecules to Activate Acetylcholinesterase for Organophosphate Poisoning - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
Small Molecules to Agonize GABAA for Nerve Gas and Organophosphate Poisoning - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Organophosphate and Carbamate Poisoning - Dormant Projects
Organophosphate and Carbamate Poisoning - Discontinued Products
Organophosphate and Carbamate Poisoning - Product Development Milestones
- Featured News & Press Releases
- Feb 21, 2016: Israeli parent patent for the use of Galantamine and Antimuscarinic Agent For Organophosphorus Poisoning awarded
Appendix
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/bi6kn4
